2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
8
Neoplasms
7
Colorectal Neoplasms
5
Recurrence
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Glioblastoma
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Radiation Pneumonitis
2
Peritoneal Neoplasms
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Patients With Any Advanced Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
nintedanib
×
Clear all
NCT01610869
2019-05-29
METRO-BIBF
University College, London
Phase 2
Completed
117 enrolled